Loading stock data…
TOI
$4.08+0.06 (+1.49%)
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
The Oncology Institute, Inc. in the Healthcare sector is trading at $4.08. Wall Street consensus targets $7.00 (4 analysts), implying a +71.6% move over the next 12 months. The stock is currently 16% below its 52-week high of $4.88, remaining 17.9% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +71.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$4.08
Potential Downside
0%
Whystock Fair Value$4.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$340.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
385.53%
Volume
Today's trading volume
3.86M
Recent News
The Oncology Institute, Inc. (NASDAQ:TOI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.00
The Oncology Institute, Inc. ( NASDAQ:TOI ) defied analyst predictions to release its quarterly results, which were...
Oncology Institute Q1 Earnings Call Highlights
Oncology Institute (NASDAQ:TOI) reported a strong start to 2026, with first-quarter revenue rising 41% year over year as the company expanded value-based care arrangements and posted record specialty pharmacy performance. Chief Executive Officer Dan Virnich said the quarter was driven by “continued
The Oncology Institute, Inc. Q1 2026 Earnings Call Summary
Moby summary of The Oncology Institute, Inc.'s Q1 2026 earnings call
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Beats Revenue Estimates
The Oncology Institute (TOI) delivered earnings and revenue surprises of +71.43% and +1.54%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Ensign Group (ENSG) Q1 Earnings Surpass Estimates
Ensign Group (ENSG) delivered earnings and revenue surprises of +3.35% and -0.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?